Th2-Oriented Immune Serum After SARS-CoV-2 Vaccination Does Not Enhance Infection In Vitro

Ning Luan, Tao Li, Yunfei Wang, Han Cao, Xingxiao Yin, Kangyang Lin, Cunbao Liu, Ning Luan, Tao Li, Yunfei Wang, Han Cao, Xingxiao Yin, Kangyang Lin, Cunbao Liu

Abstract

The relatively lower protection rate of the alum-adjuvanted inactivated severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) vaccines reminds us of the antibody-dependent enhancement (ADE) phenomenon observed in preclinical studies during the development of vaccines for Middle East respiratory syndrome coronavirus (MERS-CoV) and severe acute respiratory syndrome coronavirus 1 (SARS-CoV-1). In this study, using the S1 segment of the SARS-CoV-2 spike protein or inactivated whole SARS-CoV-2 virus as an antigen and aluminum as an adjuvant, the risk of ADE of infection with T helper 2 (Th2)-oriented immune serum from mice (N=6) and humans (N=5) was examined in immune cell lines, which show different expression patterns of Fc receptors. Neither the immune serum from alum-adjuvanted S1 subunit vaccines nor inactivated SARS-CoV-2 vaccination enhanced SARS-CoV-2 S pseudotyped virus infection in any of the tested cell lines in vitro. Because both of these Th2-oriented immune sera could block SARS-CoV-2 infection without ADE of infection, we speculate that the lower protection rate of the inactivated SARS-CoV-2 vaccine may be attributed to the lower neutralizing antibody titers induced or the pulmonary eosinophilic immunopathology accompanied by eosinophilic infiltration in the lungs upon virus exposure. Adjustment of the immunization schedule to elevate the neutralizing antibody levels and skew adjuvants toward Th1-oriented responses may be considered to increase the efficacies of both inactivated and spike protein-based subunit SARS-CoV-2 vaccines.

Trial registration: ClinicalTrials.gov NCT04510207 NCT04456595 NCT04582344 NCT04651790.

Keywords: Th2; aluminum adjuvant; antibody-dependent enhancement of infection; inactivated SARS-CoV-2 vaccine; spike protein subunit vaccine.

Conflict of interest statement

The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Copyright © 2022 Luan, Li, Wang, Cao, Yin, Lin and Liu.

Figures

Figure 1
Figure 1
Alum induced a Th2-oriented immune response, whereas nucleic acids induced a Th1-oriented response when adjuvanted with the S1 protein. (A) Immunization schedule, N=6 in each group; (B) S1-specific IgG titers of immune serum; (C) S1-specific IgG1 and IgG2a titers in immune serum; (D) IgG1/IgG2a ratio of immune serum. All of the above titers were detected in pooled serum from each immunized group, and the means and standard deviations of duplicates are shown.
Figure 2
Figure 2
Fc receptor expression patterns in immune cell lines. (A) The protein expression levels of ACE2, FcγR1 and FcγR2 were detected by Western blot. (B) The gene expression of ACE2 and more specific FcγR subtypes, including FcγR1A, FcγR2A, and FcγR2B, was detected by RT-PCR.
Figure 3
Figure 3
Th2-oriented immune serum after S1-based subunit vaccine administration does not enhance infection in vitro. (A) Pseudovirus-based neutralization assay of immune serum in Vero cells that express ACE2. (B–E) Assay of pseudovirus-based antibody-dependent enhancement of infection with immune serum in different FcγR-expressing cells. Poly(I:C)+CpG, nucleic acid-adjuvanted plus S1-purified protein immune serum; Alum, alum-adjuvanted plus S1-purified protein immune serum; Sham, serum from mice intramuscularly administered PBS instead of immunogens. All of the above analyses were performed using pooled serum from each immunized group. The means and standard deviations of duplicates are shown.
Figure 4
Figure 4
Th2-oriented immune serum after SARS-CoV-2 inactivated vaccine administration does not enhance infection in vitro. (A) Pseudovirus-based neutralization assay of human serum with low to high authentic SARS-CoV-2 neutralization titers (from 4 to 256) in Vero cells that express ACE2. The sample ID and authentic SARS-CoV-2 neutralization titer are shown in the table on the right. (B–E) Assay of pseudovirus-based antibody-dependent enhancement of infection with human serum in cells with different FcγR expression patterns. V1-V5, human sera after inactivated SARS-CoV-2 vaccination; HSC1-6: human convalescent serum. Each sample is shown separately.

References

    1. Agrawal AS, Tao X, Algaissi A, Garron T, Narayanan K, Peng B, et al. . Immunization With Inactivated Middle East Respiratory Syndrome Coronavirus Vaccine Leads to Lung Immunopathology on Challenge With Live Virus. Hum Vaccin Immunother (2016) 12(9):2351–6. doi: 10.1080/21645515.2016.1177688
    1. Tseng CT, Sbrana E, Iwata-Yoshikawa N, Newman PC, Garron T, Atmar RL, et al. . Immunization With SARS Coronavirus Vaccines Leads to Pulmonary Immunopathology on Challenge With the SARS Virus. PloS One (2012) 7(4):e35421. doi: 10.1371/journal.pone.0035421
    1. Bolles M, Deming D, Long K, Agnihothram S, Whitmore A, Ferris M, et al. . A Double-Inactivated Severe Acute Respiratory Syndrome Coronavirus Vaccine Provides Incomplete Protection in Mice and Induces Increased Eosinophilic Proinflammatory Pulmonary Response Upon Challenge. J Virol (2011) 85(23):12201–15. doi: 10.1128/JVI.06048-11
    1. Wang Q, Zhang L, Kuwahara K, Li L, Liu Z, Li T, et al. . Immunodominant SARS Coronavirus Epitopes in Humans Elicited Both Enhancing and Neutralizing Effects on Infection in Non-Human Primates. ACS Infect Dis (2016) 2(5):361–76. doi: 10.1021/acsinfecdis.6b00006
    1. Jaume M, Yip MS, Cheung CY, Leung HL, Li PH, Kien F, et al. . Anti-Severe Acute Respiratory Syndrome Coronavirus Spike Antibodies Trigger Infection of Human Immune Cells via a pH- and Cysteine Protease-Independent FcgammaR Pathway. J Virol (2011) 85(20):10582–97. doi: 10.1128/JVI.00671-11
    1. Wang SF, Tseng SP, Yen CH, Yang JY, Tsao CH, Shen CW, et al. . Antibody-Dependent SARS Coronavirus Infection Is Mediated by Antibodies Against Spike Proteins. Biochem Biophys Res Commun (2014) 451(2):208–14. doi: 10.1016/j.bbrc.2014.07.090
    1. Lee WS, Wheatley AK, Kent SJ, DeKosky BJ. Antibody-Dependent Enhancement and SARS-CoV-2 Vaccines and Therapies. Nat Microbiol (2020) 5(10):1185–91. doi: 10.1038/s41564-020-00789-5
    1. Zheng J, Wang Y, Li K, Meyerholz DK, Allamargot C, Perlman S. Severe Acute Respiratory Syndrome Coronavirus 2-Induced Immune Activation and Death of Monocyte-Derived Human Macrophages and Dendritic Cells. J Infect Dis (2021) 223(5):785–95. doi: 10.1093/infdis/jiaa753
    1. Liu L, Wei Q, Lin Q, Fang J, Wang H, Kwok H, et al. . Anti-Spike IgG Causes Severe Acute Lung Injury by Skewing Macrophage Responses During Acute SARS-CoV Infection. JCI Insight (2019) 4(4):e123158. doi: 10.1172/jci.insight.123158
    1. Zhou J, Chu H, Li C, Wong BH, Cheng ZS, Poon VK, et al. . Active Replication of Middle East Respiratory Syndrome Coronavirus and Aberrant Induction of Inflammatory Cytokines and Chemokines in Human Macrophages: Implications for Pathogenesis. J Infect Dis (2014) 209(9):1331–42. doi: 10.1093/infdis/jit504
    1. Rotondo JC, Martini F, Maritati M, Mazziotta C, Mauro GD, Lanzillotti C, et al. . SARS-CoV-2 Infection: New Molecular, Phylogenetic, and Pathogenetic Insights. Efficacy of Current Vaccines and the Potential Risk of Variants. Viruses (2021) 13(9):1687. doi: 10.3390/v13091687
    1. Iwata-Yoshikawa N, Uda A, Suzuki T, Tsunetsugu-Yokota Y, Sato Y, Morikawa S, et al. . Effects of Toll-Like Receptor Stimulation on Eosinophilic Infiltration in Lungs of BALB/c Mice Immunized With UV-Inactivated Severe Acute Respiratory Syndrome-Related Coronavirus Vaccine. J Virol (2014) 88(15):8597–614. doi: 10.1128/JVI.00983-14
    1. Honda-Okubo Y, Barnard D, Ong CH, Peng BH, Tseng CT, Petrovsky N. Severe Acute Respiratory Syndrome-Associated Coronavirus Vaccines Formulated With Delta Inulin Adjuvants Provide Enhanced Protection While Ameliorating Lung Eosinophilic Immunopathology. J Virol (2015) 89(6):2995–3007. doi: 10.1128/JVI.02980-14
    1. Roberts A, Lamirande EW, Vogel L, Baras B, Goossens G, Knott I, et al. . Immunogenicity and Protective Efficacy in Mice and Hamsters of a Beta-Propiolactone Inactivated Whole Virus SARS-CoV Vaccine. Viral Immunol (2010) 23(5):509–19. doi: 10.1089/vim.2010.0028
    1. Corbett KS, Edwards DK, Leist SR, Abiona OM, Boyoglu-Barnum S, Gillespie RA, et al. . SARS-CoV-2 mRNA Vaccine Design Enabled by Prototype Pathogen Preparedness. Nature (2020) 586(7830):567–71. doi: 10.1038/s41586-020-2622-0
    1. Corbett KS, Flynn B, Foulds KE, Francica JR, Boyoglu-Barnum S, Werner AP, et al. . Evaluation of the mRNA-1273 Vaccine Against SARS-CoV-2 in Nonhuman Primates. N Engl J Med (2020) 383(16):1544–55. doi: 10.1056/NEJMoa2024671
    1. Laczko D, Hogan MJ, Toulmin SA, Hicks P, Lederer K, Gaudette BT, et al. . A Single Immunization With Nucleoside-Modified mRNA Vaccines Elicits Strong Cellular and Humoral Immune Responses Against SARS-CoV-2 in Mice. Immunity (2020) 53(4):724–32.e727. doi: 10.1016/j.immuni.2020.07.019
    1. Jackson LA, Anderson EJ, Rouphael NG, Roberts PC, Makhene M, Coler RN, et al. . An mRNA Vaccine Against SARS-CoV-2 - Preliminary Report. N Engl J Med (2020) 383(20):1920–31. doi: 10.1056/NEJMoa2022483
    1. Walsh EE, Frenck RW, Jr, Falsey AR, Kitchin N, Absalon J, Gurtman A, et al. . Safety and Immunogenicity of Two RNA-Based Covid-19 Vaccine Candidates. N Engl J Med (2020) 383(25):2439–50. doi: 10.1056/NEJMoa2027906
    1. Guebre-Xabier M, Patel N, Tian JH, Zhou B, Maciejewski S, Lam K, et al. . NVX-CoV2373 Vaccine Protects Cynomolgus Macaque Upper and Lower Airways Against SARS-CoV-2 Challenge. Vaccine (2020) 38(50):7892–6. doi: 10.1016/j.vaccine.2020.10.064
    1. Keech C, Albert G, Cho I, Robertson A, Reed P, Neal S, et al. . Phase 1-2 Trial of a SARS-CoV-2 Recombinant Spike Protein Nanoparticle Vaccine. N Engl J Med (2020) 383(24):2320–32. doi: 10.1056/NEJMoa2026920
    1. Tian JH, Patel N, Haupt R, Zhou H, Weston S, Hammond H, et al. . SARS-CoV-2 Spike Glycoprotein Vaccine Candidate NVX-CoV2373 Immunogenicity in Baboons and Protection in Mice. Nat Commun (2021) 12(1):372. doi: 10.1038/s41467-020-20653-8
    1. HogenEsch H, O’Hagan DT, Fox CB. Optimizing the Utilization of Aluminum Adjuvants in Vaccines: You Might Just Get What You Want. NPJ Vaccines (2018) 3:51. doi: 10.1038/s41541-018-0089-x
    1. Palacios R, Batista AP, Albuquerque CSN, Patio EG, Santos JDP, Mnica TRPC, et al. . Efficacy and Safety of a COVID-19 Inactivated Vaccine in Healthcare Professionals in Brazil: The PROFISCOV Study. Soc Sci Res Net (2021). doi: 10.2139/ssrn.3822780.
    1. Al Kaabi N, Zhang Y, Xia S, Yang Y, AI Qahtani MM, Abdulrazzaq N, et al. . Effect of 2 Inactivated SARS-CoV-2 Vaccines on Symptomatic COVID-19 Infection in Adults: A Randomized Clinical Trial. JAMA (2021) 326(1):35–45. doi: 10.1001/jama.2021.8565
    1. Tanriover MD, Doganay HL, Akova M, Guner HR, Azap A, Akhan S, et al. . Efficacy and Safety of an Inactivated Whole-Virion SARS-CoV-2 Vaccine (CoronaVac): Interim Results of a Double-Blind, Randomised, Placebo-Controlled, Phase 3 Trial in Turkey. Lancet (2021) 398(10296):213–22. doi: 10.1016/S0140-6736(21)01429-X
    1. Jara A, Undurraga EA, Gonzalez C, Paredes F, Fontecilla T, Jara G, et al. . Effectiveness of an Inactivated SARS-CoV-2 Vaccine in Chile. N Engl J Med (2021) 385(10):875–84. doi: 10.1056/NEJMoa2107715
    1. Gao Q, Bao L, Mao H, Wang L, Xu K, Yang M, et al. . Development of an Inactivated Vaccine Candidate for SARS-CoV-2. Science (2020) 369(6499):77–81. doi: 10.1126/science.abc1932
    1. Wang H, Zhang Y, Huang B, Deng W, Quan Y, Wang W, et al. . Development of an Inactivated Vaccine Candidate, BBIBP-CorV, With Potent Protection Against SARS-CoV-2. Cell (2020) 182(3):713–21.e719. doi: 10.1016/j.cell.2020.06.008
    1. Wang ZJ, Zhang HJ, Lu J, Xu KW, Peng C, Huo J, et al. . Low Toxicity and High Immunogenicity of an Inactivated Vaccine Candidate Against COVID-19 in Different Animal Models. Emerg Microbes Infect (2020) 9(1):2606–18. doi: 10.1080/22221751.2020.1852059
    1. Bewley KR, Gooch K, Thomas KM, Longet S, Wiblin N, Hunter L, et al. . Immunological and Pathological Outcomes of SARS-CoV-2 Challenge Following Formalin-Inactivated Vaccine in Ferrets and Rhesus Macaques. Sci Adv (2021) 7(37):eabg7996. doi: 10.1126/sciadv.abg7996
    1. Yuan L, Tang Q, Zhu H, Guan Y, Cheng T, Xia N. SARS-CoV-2 Infection and Disease Outcomes in Non-Human Primate Models: Advances and Implications. Emerg Microbes Infect (2021) 10(1):1881–9. doi: 10.1080/22221751.2021.1976598
    1. He Y, Li J, Heck S, Lustigman S, Jiang S. Antigenic and Immunogenic Characterization of Recombinant Baculovirus-Expressed Severe Acute Respiratory Syndrome Coronavirus Spike Protein: Implication for Vaccine Design. J Virol (2006) 80(12):5757–67. doi: 10.1128/JVI.00083-06
    1. Ren W, Sun H, Gao GF, Chen J, Sun S, Zhao R, et al. . Recombinant SARS-CoV-2 Spike S1-Fc Fusion Protein Induced High Levels of Neutralizing Responses in Nonhuman Primates. Vaccine (2020) 38(35):5653–8. doi: 10.1016/j.vaccine.2020.06.066
    1. Wang N, Shang J, Jiang S, Du L. Subunit Vaccines Against Emerging Pathogenic Human Coronaviruses. Front Microbiol (2020) 11:298. doi: 10.3389/fmicb.2020.00298
    1. Liu Y, Soh WT, Kishikawa JI, Hirose M, Nakayama EE, Li S, et al. . An Infectivity-Enhancing Site on the SARS-CoV-2 Spike Protein Targeted by Antibodies. Cell (2021) 184(13):3452–66.e3418. doi: 10.1016/j.cell.2021.05.032
    1. Wang S, Peng Y, Wang R, Jiao S, Wang M, Huang W, et al. . Characterization of Neutralizing Antibody With Prophylactic and Therapeutic Efficacy Against SARS-CoV-2 in Rhesus Monkeys. Nat Commun (2020) 11(1):5752. doi: 10.1038/s41467-020-19568-1
    1. Zhou Y, Liu Z, Li S, Xu W, Zhang Q, Silva IT, et al. . Enhancement Versus Neutralization by SARS-CoV-2 Antibodies From a Convalescent Donor Associates With Distinct Epitopes on the RBD. Cell Rep (2021) 34(5):108699. doi: 10.1016/j.celrep.2021.108699
    1. Che Y, Liu X, Pu Y, Zhou M, Zhao Z, Jiang R, et al. . Randomized, Double-Blinded and Placebo-Controlled Phase II Trial of an Inactivated SARS-CoV-2 Vaccine in Healthy Adults. Clin Infect Dis (2021) 73(11):e3949–55. doi: 10.1093/cid/ciaa1703
    1. Cao H, Yang S, Wang Y, Luan N, Yin X, Lin K, et al. . An Established Th2-Oriented Response to an Alum-Adjuvanted SARS-CoV-2 Subunit Vaccine Is Not Reversible by Sequential Immunization With Nucleic Acid-Adjuvanted Th1-Oriented Subunit Vaccines. Vaccines (Basel) (2021) 9(11):1261. doi: 10.3390/vaccines9111261
    1. Cao H, Wang Y, Luan N, Liu C. Immunogenicity of Varicella-Zoster Virus Glycoprotein E Formulated With Lipid Nanoparticles and Nucleic Immunostimulators in Mice. Vaccines (Basel) (2021) 9(4):310. doi: 10.3390/vaccines9040310
    1. Wang P. Natural and Synthetic Saponins as Vaccine Adjuvants. Vaccines (Basel) (2021) 9(3):222. doi: 10.3390/vaccines9030222
    1. Lefeber DJ, Benaissa-Trouw B, Vliegenthart JF, Kamerling JP, Jansen WTM, Kraaijeveld K, et al. . Th1-Directing Adjuvants Increase the Immunogenicity of Oligosaccharide-Protein Conjugate Vaccines Related to Streptococcus Pneumoniae Type 3. Infect Immun (2003) 71(12):6915–20. doi: 10.1128/IAI.71.12.6915-6920.2003
    1. Mountford AP, Fisher A, Wilson RA. The Profile of IgG1 and IgG2a Antibody Responses in Mice Exposed to Schistosoma Mansoni. Parasite Immunol (1994) 16(10):521–7. doi: 10.1111/j.1365-3024.1994.tb00306.x
    1. Nie J, Li Q, Wu J, Zhao C, Hao H, Liu H, et al. . Quantification of SARS-CoV-2 Neutralizing Antibody by a Pseudotyped Virus-Based Assay. Nat Protoc (2020) 15(11):3699–715. doi: 10.1038/s41596-020-0394-5
    1. Li D, Edwards RJ, Manne K, Martinez DR, Schafer A, Alam SM, et al. . In Vitro and In Vivo Functions of SARS-CoV-2 Infection-Enhancing and Neutralizing Antibodies. Cell (2021) 184(16):4203–19.e4232. doi: 10.1016/j.cell.2021.06.021
    1. Wan Y, Shang J, Sun S, Tai W, Chen J, Geng Q, et al. . Molecular Mechanism for Antibody-Dependent Enhancement of Coronavirus Entry. J Virol (2020) 94(5):e02015–19. doi: 10.1128/JVI.02015-19
    1. Yip MS, Leung HL, Li PH, Cheung CY, Dutry I, Li D, et al. . Antibody-Dependent Enhancement of SARS Coronavirus Infection and Its Role in the Pathogenesis of SARS. Hong Kong Med J (2016) 22(3 Suppl 4):25–31.
    1. Zhang Y, Li D, Zhao H, Wang L, Liao Y, Li X, et al. . The Role of Multiple SARS-CoV-2 Viral Antigens in a Vaccine-Induced Integrated Immune Response. Vaccine (2021) 39(18):2500–3. doi: 10.1016/j.vaccine.2021.03.067
    1. Baden LR, El Sahly HM, Essink B, Kotloff K, Frey S, Novak R, et al. . Efficacy and Safety of the mRNA-1273 SARS-CoV-2 Vaccine. N Engl J Med (2021) 384(5):403–16. doi: 10.1056/NEJMoa2035389
    1. Heath PT, Galiza EP, Baxter DN, Boffito M, Browne D, Burns F, et al. . Safety and Efficacy of NVX-CoV2373 Covid-19 Vaccine. N Engl J Med (2021) 385(13):1172–83. doi: 10.1056/NEJMoa2107659
    1. Polack FP, Thomas SJ, Kitchin N, Absalon J, Gurtman A, Lockhart S, et al. . Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine. N Engl J Med (2020) 383(27):2603–15. doi: 10.1056/NEJMoa2034577
    1. Li D, Luan N, Li J, Zhao H, Zhang Y, Long R, et al. . Waning Antibodies From Inactivated SARS-CoV-2 Vaccination Offer Protection Against Infection Without Antibody-Enhanced Immunopathology in Rhesus Macaque Pneumonia Models. Emerg Microbes Infect (2021) 10(1):2194–8. doi: 10.1080/22221751.2021.2002670
    1. DiPiazza AT, Leist SR, Abiona OM, Moliva JI, Werner A, Minai M, et al. . COVID-19 Vaccine mRNA-1273 Elicits a Protective Immune Profile in Mice That is Not Associated With Vaccine-Enhanced Disease Upon SARS-CoV-2 Challenge. Immunity (2021) 54(8):1869–82.e1866. doi: 10.1016/j.immuni.2021.06.018
    1. Ella R, Reddy S, Jogdand H, Sarangi H, Ganneru H, Prasad H, et al. . Safety and Immunogenicity of an Inactivated SARS-CoV-2 Vaccine, BBV152: Interim Results From a Double-Blind, Randomised, Multicentre, Phase 2 Trial, and 3-Month Follow-Up of a Double-Blind, Randomised Phase 1 Trial. Lancet Infect Dis (2021) 21(7):950–61. doi: 10.1016/S1473-3099(21)00070-0
    1. Ganneru B, Jogdand H, Daram VK, Das D, Molugu NR, Prasad SD, et al. . Th1 Skewed Immune Response of Whole Virion Inactivated SARS CoV 2 Vaccine and its Safety Evaluation. iScience (2021) 24(4):102298. doi: 10.1016/j.isci.2021.102298
    1. Liang JG, Su D, Song TZ, Zeng Y, Huang W, Wu J, et al. . S-Trimer, a COVID-19 Subunit Vaccine Candidate, Induces Protective Immunity in Nonhuman Primates. Nat Commun (2021) 12(1):1346. doi: 10.1038/s41467-021-21634-1
    1. Richmond P, Hatchuel L, Dong M, Ma B, Hu B, Smolenov I, et al. . Safety and Immunogenicity of S-Trimer (SCB-2019), a Protein Subunit Vaccine Candidate for COVID-19 in Healthy Adults: A Phase 1, Randomised, Double-Blind, Placebo-Controlled Trial. Lancet (2021) 397(10275):682–94. doi: 10.1016/S0140-6736(21)00241-5

Source: PubMed

Sponsors and Collaborators

Medical Conditions

Drug Interventions

3
Subscribe